Podcasts

Stacie Dusetzina, PhD, associate professor of health policy, Vanderbilt University Medical Center, joins the show to expound on the changes that have been made to Medicare Part D since its inception during the Bush administration, how Part D is failing the older population in need of expensive drugs, and the counterintuitive state of generic drug affordability for Part D recipients.

Chadi welcomes back Alison Bateman-House, MPH, PhD, medical ethicist at New York University’s School of Medicine, to break down COVID-19 vaccine distribution and mandates.

Rohin Francis, cardiologist in the UK, brings his expertise and unique sense of humor to the show to share how he’s combined comedy with medical education through his Twitter and YouTube presence, how he sifts through the vast expanse of COVID-19 research for data that is useful and legitimate, the apparent inability to have an open scientific debate on Twitter without being chastised or judged for your viewpoints, and so much more.

Aaron Goodman, MD, hematologist/oncologist, University of California San Diego, and Jatin Shah, MD, executive vice president and chief medical officer, Karyopharm Therapeutics, join the show for a deep consideration of oncology drug approvals in the context of RCTs, RWE, surrogate endpoints, and outcomes.

In an enthralling yet informative roundtable discussion, Chadi hosts Saurabh Jha, MD, radiologist and frequent guest of the show; Vinay Prasad, MD, MPH, hematologist/oncologist and former guest of the show; and Sally “Loyal Listener,” patient advocate, to breakdown 2020 like only they can.

Rafael Fonseca, MD, interim director of Mayo Clinic Cancer Center, shares with Chadi his picks for the most clinically applicable multiple myeloma studies coming out of the ASH virtual meeting, including notes on transplantation, frontline therapy, the “belle of the ball” bispecific antibodies, CAR-T therapies, and MRD monitoring.

Laura Lee, JD, a lawyer by training and journalist in North Carolina, brings her unique perspective to the show to discuss how language used on social media to describe the outcomes of clinical trials and the tolerance of therapies in a patient population can be damaging to patients on an individual level. She expresses some

Yousuf Zafar, MD, GI oncologist and associate professor of medicine, Duke University, highlights perspectives that are missing from the “general rubric” of value-based care in oncology, how real-world evidence (RWE) can help augment takeaways from clinical trial data, issues of capturing the patient voice in real-world data and electronic health records, and how the FDA is utilizing RWE for expanding drug indications.